Digipath, Inc. DIGP
We take great care to ensure that the data presented and summarized in this overview for Digipath, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in DIGP
Top Purchases
Top Sells
About DIGP
Digipath, Inc., together with its subsidiaries, provides cannabis and hemp lab testing services in Las Vegas to Nevada licensed medical marijuana enterprises. It also provides testing, cannabis education and training, and cannabis news coverage to the cannabis industry. The company operates as a testing laboratory facility for cannabis, cannabis infused products, hemp, and other botanical nutraceuticals to serve growers, dispensaries, caregivers, producers, patients, and end users of cannabis and botanical products. In addition, its labs screen medicinal and recreational cannabis for potentially harmful contaminants, including residual solvents; moisture; water activity; visual inspection; pesticides; heavy metals, such as mercury, arsenic, lead, cadmium, chromium, and nickel; biological toxins comprising aflatoxin and ocratoxins; and microbial contaminants consisting of E. coli, salmonella, coliforms, aspergillus, gram negative bacteria, total aerobic bacteria, and mold and yeast. Digipath, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.
Insider Transactions at DIGP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 21
2021
|
A Stone Douglass Chairman and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,500,000
+50.0%
|
-
|
|
Jul 01
2021
|
Todd Denkin President |
BUY
Grant, award, or other acquisition
|
Direct |
1,500,000
+39.38%
|
-
|
|
Jun 25
2021
|
Bruce I Raben Director |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+9.47%
|
-
|
|
Jun 25
2021
|
Dennis Hartmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+27.78%
|
-
|
|
Jun 02
2021
|
Bruce I Raben Director |
BUY
Grant, award, or other acquisition
|
Direct |
840,000
+28.19%
|
-
|
|
Mar 25
2021
|
Bruce I Raben Director |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+13.33%
|
-
|
|
Mar 25
2021
|
Dennis Hartmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Mar 25
2021
|
Edmond De Frank Director |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Mar 25
2021
|
Todd A Peterson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
266,430
+6.51%
|
-
|
|
Dec 30
2020
|
Bruce I Raben Director |
BUY
Grant, award, or other acquisition
|
Direct |
900,000
+45.0%
|
$0
$0.02 P/Share
|
|
Dec 25
2020
|
Todd A Peterson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
728,155
+16.97%
|
-
|
|
Sep 25
2020
|
Todd A Peterson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
657,895
+18.84%
|
-
|